No abstract

Background Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries and its prevalence is increasing. As an emerging therapy with a promising efficacy, immunotherapy has been extensively applied in the treatment of solid tumors. In addition, chromatin regulators (CRs), as essential upstream regulators of epigenetics, play a significant role in tumorigenesis and cancer development. Methods CRs and immune checkpoint-related genes (ICRGs) were obtained from the previous top research. The Genome Cancer Atlas (TCGA) was utilized to acquire the mRNA expression and clinical information of patients with EC. Correlation analysis was utilized for screen CRs-related ICRGs (CRRICRGs). By Cox regression and least absolute shrinkage and selection operator (LASSO) analysis, prognosis related CRRICRGs were screened out and risk model was constructed. The Kaplan–Meier curve was used to estimate the prognosis between high- and low-risk group. By comparing the IC50 value, the drugs sensitivity difference was explored. We obtained small molecule drugs for the treatment of UCEC patients based on CAMP dataset. Results We successfully constructed a 9 CRRICRs-based prognostic signature for patients with UCEC and found the riskscore was an independent prognostic factor. The results of functional analysis suggested that CRRICRGs may be involved in immune processes associated with cancer. Immune characteristics analysis provided further evidence that the CRRICRGs-based model was correlated with immune cells infiltration and immune checkpoint. Eight small molecule drugs that may be effective for the treatment of UCEC patients were screened. Effective drugs identified by drug sensitivity profiling in high- and low-risk groups. Conclusion In summary, our study provided novel insights into the function of CRRICRGs in UCEC. We also developed a reliable prognostic panel for the survival of patients with UCEC.

Objective: To investigate the relationship between serum magnesium and metabolic syndrome (MetS) and serum metabolic parameters in endometrial cancer (EC) patients.Patients and methods: A retrospective study was designed to collect medical records of 291 patients diagnosed with EC from July 2016 to May 2021. Independent samples t-test, ANOVA, and chi-square test were used to compare whether the clinical characteristics of EC patients were statistically different across groups. Correlation analysis and partial correlation analysis were performed to determine whether there was a relationship between serum magnesium and the incidence of MetS and its components in EC patients.Results: Serum magnesium concentration was lower in postmenopausal patients (0.94±0.08 vs. 0.91±0.07; p=0.018) or patients with diabetes mellitus (DM) (0.90±0.09 vs. 0.93±0.07; p=0.005). EC patients with hypomagnesemia had a higher BMI (25.10±4.31 vs. 24.41±3.93 vs. 24.33±3.12; p=0.014) and a higher prevalence of DM (55.6% vs. 22.5% vs. 20.7%; p=0.006) and higher TG (2.29±2.95 vs 1.62±0.91 vs 1.47±0.60; p=0.046) than the other groups. The correlation between the number of MetS criteria patients met and serum magnesium concentration was calculated and there is negative correlation between them (r=-0.201; p<0.001). Significant negative correlations were also found between total serum magnesium and TG (r=-0.147; p=0.025), large waist circumference (LWC) (r=-0.133; p=0.023) and the incidence of MetS in EC patients (r=-0.101; p=0.013) after adjusting for multiple variables.Conclusions: In patients with EC, during the period of treatment, supplementation with magnesium may improve the prognosis outcome. Serum magnesium may also be a novel parameter when investigating the effect of MetS on EC.